Leukemia drug study probes thinking and memory side effects
NCT ID NCT07638007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive changes, helping guide future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tyrosine kinase inhibitor (TKI) therapy
- What this could lead to
- If successful, this could help doctors understand whether TKIs affect brain function and quality of life in leukemia patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear differences, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester NCORP Research Base
RECRUITINGRochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can 3D-Printed models unlock personalized blood cancer therapies?
- Could a protein blocker quiet Leukemia's alarm system?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?